Team:Fatih Turkey/LALF

From 2011.igem.org

(Difference between revisions)
 
(27 intermediate revisions not shown)
Line 44: Line 44:
}
}
html, body, div, span, object, iframe, h1, h2, h3, h4, h5, h6, blockquote, pre, a, abbr, acronym, address,
html, body, div, span, object, iframe, h1, h2, h3, h4, h5, h6, blockquote, pre, a, abbr, acronym, address,
-
code, del, dfn, em, img, q, dl, dt, dd, ol, ul, li, fieldset, form, label, legend, table, caption, tbody, tfoot, thead, tr, th, td
+
code, del, dfn, em, img, q, dl, dt, dd, ul, li, fieldset, form, label, legend, table, caption, tbody, tfoot, thead, tr, th, td
{
{
margin:0;
margin:0;
Line 211: Line 211:
#header .logo{
#header .logo{
float: left;
float: left;
-
margin-top: 25px;
+
margin-top: 15px;
margin-left: 20px;
margin-left: 20px;
}
}
Line 227: Line 227:
}
}
.nav-wrapper{
.nav-wrapper{
-
margin: 0px 30px 0px 0px;
+
margin: 0px 90px 0px 0px;
float:right;
float:right;
}
}
Line 249: Line 249:
font-weight: normal;
font-weight: normal;
display: block; /*background of menu items (default state)*/
display: block; /*background of menu items (default state)*/
-
padding: 34px 27px 10px 17px;
+
padding: 34px 20px 10px 17px;
text-decoration: none;
text-decoration: none;
}
}
Line 485: Line 485:
<div id="header-whole">
<div id="header-whole">
<div id="header">
<div id="header">
-
<a href="https://2011.igem.org/" style="position:absolute; right:10px; top 5px; color: #343434; font-family: sans-serif; font-size: 11px; z-index: 1000;">&lArr; Back to iGem 2011 HomePage</a>
+
<a href="https://2011.igem.org/" style="position:absolute; right:10px; top:5px;"><img src="https://static.igem.org/mediawiki/2011/9/9c/Igem_basic_logo.png"/></a>
<!-- Logo -->
<!-- Logo -->
<div>
<div>
Line 503: Line 503:
</li>
</li>
<li>
<li>
-
<a href="https://2011.igem.org/Team:Fatih_Turkey/Project">Project<span>Rainbow Graveyard</span></a>
+
<a href="https://2011.igem.org/Team:Fatih_Turkey/Project">Project</a>
<ul>
<ul>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Project">Overall Project</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Project">Overall Project</a></li>
Line 510: Line 510:
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Biofilm">Biofilm</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Biofilm">Biofilm</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Experiments">Experiments</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Experiments">Experiments</a></li>
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Results">Results</a></li>
+
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Parts">Parts</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Future_Plan">Future Plan</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Future_Plan">Future Plan</a></li>
</ul>
</ul>
</li>
</li>
<li>
<li>
-
<a href="https://2011.igem.org/Team:Fatih_Turkey/Biobricks">Biobricks</a>
+
<a href="https://2011.igem.org/Team:Fatih_Turkey/Data_Page">Data Page</a>
-
<ul>
+
</li>
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Parts">Parts</a></li>
+
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Team">Team</a>
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Devices">Devices</a></li>
+
<ul>
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Modelling">Modelling</a></li>
+
                                                                                <li><a  
-
</ul>
+
href="https://2011.igem.org/Team:Fatih_Turkey/Members">Members</a></li>
-
</li>
+
                                                                                  <li><a  
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Safety">Safety</a></li>
+
href="https://2011.igem.org/Team:Fatih_Turkey/Gallery">Gallery</a></li>
 +
                                                                                  <li><a  
 +
href="https://2011.igem.org/Team:Fatih_Turkey/Europe_Jamboree">Europe Jamboree</a></li>
 +
</ul>
 +
</li>
<li>
<li>
<a href="https://2011.igem.org/Team:Fatih_Turkey/Human_Practice">Human Practice</a>
<a href="https://2011.igem.org/Team:Fatih_Turkey/Human_Practice">Human Practice</a>
<ul>
<ul>
-
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Sporocide">Sporocide</a></li>
+
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/Sporocide">Sporicide</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/iGEM_for_7_to_77">iGEM for 7 to 77</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/iGEM_for_7_to_77">iGEM for 7 to 77</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/game">Game</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/game">Game</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/canvas_times">Canvas Times</a></li>
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/canvas_times">Canvas Times</a></li>
 +
                                                                                <li><a
 +
href="https://2011.igem.org/Team:Fatih_Turkey/Safety">Safety</a></li>
 +
<li><a href="https://2011.igem.org/Team:Fatih_Turkey/collaboration">Collaboration</a></li>
</ul>
</ul>
</li>
</li>
Line 539: Line 546:
</ul>
</ul>
</li>
</li>
-
</ul>
+
                                                            </ul>
</div>
</div>
</div>
</div>
Line 561: Line 568:
<!-- post container -->
<!-- post container -->
<div>
<div>
-
<div class="meta-left-full">
+
<div class="meta-left-full">
-
  <p style="font-family: Verdana, Arial, SunSans-Regular, sans-serif;font-size:12px;">Lipopolysaccharide (LPS), or endotoxin, is the major mediator of septic shock, a serious complication of Gram-negative bacterial infections in humans. Molecules that bind LPS and neutralize its biological effects or enhance its clearance could have important clinical applications. Limulus anti-LPS factor (LALF) binds LPS tightly, and, in animal models, reduces mortality when administered before or after LPS challenge or bacterial infection. The wedge-shaped molecule has a striking charge distribution and amphipathicity that suggest how it can insert into membranes. The binding site for LPS probably involves an extended amphipathic loop, and it has been proposed that two mammalian LPS-binding proteins will have a similar loop. The amphipathic loop structure may be used in the design of molecules with therapeutic properties against septic shock.</p>
+
 
 +
 
 +
 
 +
 
 +
<p>As we know, seawater is a virtual &quot;bacterial soup&quot;. Typical near-shore areas that form the prime habitat of the horseshoe crab can easily contain over one billion Gram-negative bacteria per milliliter of seawater. Thus, the horseshoe crab is constantly threatened with infection. Unlike mammals, including humans, the horseshoe crab lacks an immune system; it cannot develop antibodies to fight infection. However, the horseshoe crab does contain a number of compounds that will bind to and inactivate bacteria, fungi, and viruses. Anti-LPS factors that are synthesized in the blood cells of crab are part of this primitive &quot;immune&quot; system.<br />
 +
  Lots of horseshoe crabs are collected by some manufacture companies and their blood is extracted in some laboratories. During the extraction process, up to 30% of the animal's blood is removed. Research has shown that once returned to the water, the horseshoe crab's blood volume rebounds in about a week. But, it is also noted that a number of crabs which cannot be undervalued are also dying during the process.<br />
 +
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src="https://static.igem.org/mediawiki/2011/2/2d/590_crash_blood.png" alt="590_crash_blood.png (613×359)"/> <br />
 +
</p>
 +
<p>In our project, we aim to produce those factors by using the synthetic biology. In this way, we can obtain them without extracting blood and hurting any crab. Additionally, the possible medication will be gathered cheaper.<br />
 +
  In our project, mainly we study on a protein that is gathered from horseshoe crab (<em>limulus polyphemus), </em>limulus anti lipopolysaccharide factor (LALF). By the help of this protein, we planned to stop bacteria growth in vitro situations. </p>
 +
<p> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src="https://static.igem.org/mediawiki/2011/1/1b/Ppk%C4%B1jougj.png" alt="Ppkıjougj.png (393×369)" width="381" height="357"/></p>
 +
<p>Lipopolysaccharide (LPS), or endotoxin, is the major mediator of septic shock, a serious complication of Gram-negative bacterial infections in humans. Molecules that bind LPS and neutralize its biological effects or enhance its clearance could have important clinical applications. Limulus anti-LPS factor (LALF) binds LPS tightly, and, in animal models, reduces mortality when administered before or after LPS challenge or bacterial infection. The wedge-shaped molecule has a striking charge distribution and amphipathicity that suggest how it can insert into membranes. The binding site for LPS probably involves an extended amphipathic loop, and it has been proposed that two mammalian LPS-binding proteins will have a similar loop. The amphipathic loop structure may be used in the design of molecules with therapeutic properties against septic shock.<br />
 +
To make it possible, we use Bacillus Subtilis as a host; because it is supposed that this bacterium cannot be affected by LALF. Preventing such possibilities during our experiments will help us to get the best and the clearest results. <br />
 +
On the other hand, we want to apply our anti-LPS factor on a surface as a coat in order to obtain an anti-gram negative bacterial surface. Normally, B.subtilis has the ability to produce biofilm. This complex media may also include some components and protein that are synthesized by bacteria. We think that after the production of LALF, the protein can pass to biofilm with the help of signal peptides we added. As long as LALF remains in the biofilm, the surface that is covered with that biofilm material will not be infected by gram negatives.</p>
 +
<p><img src="https://static.igem.org/mediawiki/2011/4/4d/Mustafa--lalf.png" alt="Mustafa--lalf.png (610×496)" width="550" height="440"/><img src="https://static.igem.org/mediawiki/2011/c/c9/Gjhjg%C3%B6hk%C3%A7j..png" alt="Gjhjgöhkçj..png (592×956)" width="274" height="442"/><br />
 +
</p>
 +
<p>The LPS coat of gram negative bacteria is an important reason of endotoxin and septic shock. LALF binds to that LPS coat and inhibits the growth of bacteria. This ability is very crucial and may be very useful considering the diseases and pandemics that are caused by gram negatives. Our project suggests a possible prevention for such circumstances.<br />
 +
  Also, by killing spores of B.subtilis on the biofilm surface with aqueous dissolved oxygen, ascorbic acid, and copper ions, we will try to perform a sterilized coating material which will possess a protective feature against infectious gram negative bacteria. </p>
 +
 
 +
 
-
<p style="font-family: Verdana, Arial, SunSans-Regular, sans-serif;font-size:12px;">Horseshoe crabs (Limulus polyphemus and Tachypleus tridentatus) are ancient arachnids that possess a primitive circulatory system, the hemolymph, containing only one kind of cell, the hemocyte. Exposure of hemocytes to bacterial endotoxins [lipopolysaccharide (LPS)] results in the activation of an intracellular coagulation cascade (Iwanaga et al., 1986), a defense against microbial invasion. The system consists of several proteins, including one that may inhibit the cascade, called anti-LPS factor(Morita et al., 1985). Limulus anti-LPS factor (LALF) is a small (101 amino acids), basic protein (Aketagawa et al., 1986; Muta et al., 1987), which binds and neutralizes LPS (Wainwright et al., 1990) and has a strong anti-bacterial effect on the growth of Gram-negative R-type bacteria (Morita et al., 1985)(22). Our interest in determining the crystal structure of LALF arose from its potential in designing molecules that would have therapeutic properties in humans. It has been proposed that LALF has sequence similarity with ct-lactalbumin, a protein that binds LPS in vitro (Aketagawa et al., 1986).</p>
+
<h3>REFERENCES</h3>
-
<img src="https://static.igem.org/mediawiki/2011/b/b5/Lalf.png"/>
+
<ol>
-
<p style="font-family: Verdana, Arial, SunSans-Regular, sans-serif;font-size:12px;">LALF recognizes the lipid A portion of individual soluble LPS molecules (Warren et al., 1992), which are obtained below the critical micellar concentration. The simplest molecules that bind lipid A with high affinity are the polymyxin family of antibiotics; these are positively charged amphipathic cyclic oligopeptides linked to a single fatty acid (Morrison and Jacobs, 1976).</p>
+
<li>Alpert G, Baldwin G, Thompson C, Wainwright N, Novitsky T J, Gillis , Parsonnet J, Fleisher G R, Siber G R. Limulus antilipopolysaccharide
-
<img src="https://static.igem.org/mediawiki/2011/1/17/Lalf2.png"/>
+
factor protects rabbits from meningococcal endotoxin shock. J Infect Dis. 1992;165:494–500. [PubMed]</li>
-
<small>Fig3, Fig4 (A. Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.)</small>
+
<li>Bannerman D D, Goldblum S E. Endotoxin induces endothelial barrier dysfunction through protein tyrosine phosphorylation. Am J Physiol. 1997;273:L217–L226. [PubMed]
-
<img src="https://static.igem.org/mediawiki/2011/1/16/Lalf3.png"/>
+
</li>
-
<small>Freeze fracture electron micrographs of LPS. Alone (A), in the presence of LALF supernatant (B) and precipitation (C).( Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis
+
<li>Battafaraono R J, Dahlberg P S, Ratz C A, Johnston J W, Gray B H, Haseman J R, Mayo K H, Dunn D L. Peptide derivatives of three distinct
-
Jorg ANDR¨A, Jorg HOWE, Patrick GARIDEL, Manfred R OSSLE, Walter RICHTER§, Jos´e LEIVA-LE ´ON_, Ignacio</small>
+
lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery. 1995;118:318–324. [PubMed]</li>
 +
<li>Cooperstock M S. Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother. 1974;6:422–425. [PMC free article] [PubMed]</li>
 +
<li>Evans T J, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human
 +
bactericidal/permeability-increasing protein in an animal model of gram negative sepsis. J Infect Dis. 1995;171:153–160. [PubMed]</li>
 +
<li>Fletcher M A, Mckena T M, Quance J L, Wainwright N R, Williams T J. Lipopolysaccharide detoxification by endotoxin neutralizing protein. J
 +
Surg Res. 1993;55:147–154. [PubMed]</li>
 +
<li>Frey E A, Miller D S, Jahr T G, Sundan A, Bazil V, Espevik T, Finlay B B, Wright S D. Soluble CD14 participates in the response of cells to
 +
lipopolysaccharide. J Exp Med. 1992;176:1665–1671. [PMC free article] [PubMed]</li>
 +
<li>Goldblum S E, Brann T W, Ding X, Pugin J, Tobias P S. Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. J Clin Invest. 1994;93:692–702. [PMC free article] [PubMed]</li>
 +
<li>Goldblum S E, Ding X, Brann T W, Campbell-Washington J. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap
 +
formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: concurrent F-actin depolymerization and new actin
 +
synthesis. J Cell Physiol. 1993;157:13–23. [PubMed]</li>
 +
<li>Hirata M, Zhong J, Wright S C, Larrick J W. Structure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res.
 +
1995;392:317–326. [PubMed]</li>
 +
<li>Hoess A, Watson S, Siber G R, Liddington R. Crystal structure of endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS
 +
factor, at 1.5 A resolution. EMBO J. 1993;12:3351–3356. [PMC free article] [PubMed]</li>
 +
<li>Levine D M, Parker T S, Donelly T M, Walsh A, Rubin A L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl
 +
Acad Sci USA. 1993;90:12040–12044. [PMC free article] [PubMed]</li>
 +
<li>Morita T, Ohtsubo S, Nakamura T, Tanaka S, Iwanaga S, Ohashi K, Niwa M. Isolation and biological activities of limulus anticoagulant
 +
(anti-LPS factor) which interacts with lipopolysaccharide (LPS) J Biochem (Tokyo) 1985;97:1611–1620. [PubMed]</li>
 +
<li>Morrison D C, Jacobs D M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry.
 +
1976;13:813–818. [PubMed]</li>
 +
<li>Muta T, Miyata T, Tokunaga F, Nakamura T, Iwanaga S. Primary structure of anti-lipopolysaccharide factor from American horseshoe crab,
 +
Limulus polyphemus. J Biochem (Tokyo) 1987;101:1321–1330. [PubMed]</li>
 +
<li>Netea M G, Demacker P N M, Kullberg B J, Boerman O C, Verschueren I, Stalenhoef A F H, van der Meer J W M. Low-density lipoprotein
 +
receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest. 1996;97:1366–1372.
 +
[PMC free article] [PubMed]</li>
 +
<li>Ulevitch R J, Tobias P S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol. 1994;6:125–130.
 +
[PubMed]
 +
</li>
 +
<li>Wainwright N R, Miller R J, Paus E, Novitsky T J, Fletcher M A, McKenna T M, Williams T. Endotoxin binding and neutralizing activity by a
 +
protein from Limulus polyphemus. In: Levin J, Alving C R, Munford R S, Stutz P L, editors. Cellular and molecular aspects of endotoxin
 +
reactions. New York, N.Y: Elsevier Science Publishers; 1990. pp. 315–325.</li>
 +
<li>Warren H S, Novitsky T J, Bucklin A, Kania S A, Siber G R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other
 +
gram-negative bacteria. Infect Immun. 1987;55:1668–1673. [PMC free article] [PubMed]</li>
 +
<li>Weinstein S L, June C H, DeFranco A L. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated
 +
by CD14. J Immunol. 1993;151:3829–3838. [PubMed]</li>
 +
<li>A. Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.</li>
 +
<li>Lihua Wu, Chao-Ming Tsai and Carl E. Frasch.A method purification of bacterial R-type LPS.</li>
 +
<li>Kloczewiak, M., Black, K. M., Loiselle, P., Cavaillon, J. M., Wainwright, N., and Warren, H. S. (1994) J. Infect. Dis. 170, 1490–1497</li>
 +
<li>http://www.horseshoecrab.org</li>
 +
</ol>
</div>
</div>
    </div>
    </div>
Line 591: Line 658:
<div>
<div>
<h3 style="color:#BBB;">Sponsors</h3>
<h3 style="color:#BBB;">Sponsors</h3>
-
<img src="https://static.igem.org/mediawiki/2011/6/69/Tubitak.png"/>
+
<img height="100" src="https://static.igem.org/mediawiki/2011/7/72/Tubitak_-_Kopya.png"/>
<a href="http://www.sentegen.com">
<a href="http://www.sentegen.com">
-
<img src="https://static.igem.org/mediawiki/2011/d/d8/Sentegen.jpg"/></a>
+
<img height="100" src="https://static.igem.org/mediawiki/2011/2/2d/Sentegennnn.png"/></a>
</div>
</div>
</div>
</div>

Latest revision as of 01:06, 29 October 2011

deneme baslik

Project

LALF (Anti-LPS)

As we know, seawater is a virtual "bacterial soup". Typical near-shore areas that form the prime habitat of the horseshoe crab can easily contain over one billion Gram-negative bacteria per milliliter of seawater. Thus, the horseshoe crab is constantly threatened with infection. Unlike mammals, including humans, the horseshoe crab lacks an immune system; it cannot develop antibodies to fight infection. However, the horseshoe crab does contain a number of compounds that will bind to and inactivate bacteria, fungi, and viruses. Anti-LPS factors that are synthesized in the blood cells of crab are part of this primitive "immune" system.
Lots of horseshoe crabs are collected by some manufacture companies and their blood is extracted in some laboratories. During the extraction process, up to 30% of the animal's blood is removed. Research has shown that once returned to the water, the horseshoe crab's blood volume rebounds in about a week. But, it is also noted that a number of crabs which cannot be undervalued are also dying during the process.
                                         590_crash_blood.png (613×359)

In our project, we aim to produce those factors by using the synthetic biology. In this way, we can obtain them without extracting blood and hurting any crab. Additionally, the possible medication will be gathered cheaper.
In our project, mainly we study on a protein that is gathered from horseshoe crab (limulus polyphemus), limulus anti lipopolysaccharide factor (LALF). By the help of this protein, we planned to stop bacteria growth in vitro situations. 

                                                                Ppkıjougj.png (393×369)

Lipopolysaccharide (LPS), or endotoxin, is the major mediator of septic shock, a serious complication of Gram-negative bacterial infections in humans. Molecules that bind LPS and neutralize its biological effects or enhance its clearance could have important clinical applications. Limulus anti-LPS factor (LALF) binds LPS tightly, and, in animal models, reduces mortality when administered before or after LPS challenge or bacterial infection. The wedge-shaped molecule has a striking charge distribution and amphipathicity that suggest how it can insert into membranes. The binding site for LPS probably involves an extended amphipathic loop, and it has been proposed that two mammalian LPS-binding proteins will have a similar loop. The amphipathic loop structure may be used in the design of molecules with therapeutic properties against septic shock.
To make it possible, we use Bacillus Subtilis as a host; because it is supposed that this bacterium cannot be affected by LALF. Preventing such possibilities during our experiments will help us to get the best and the clearest results. 
On the other hand, we want to apply our anti-LPS factor on a surface as a coat in order to obtain an anti-gram negative bacterial surface. Normally, B.subtilis has the ability to produce biofilm. This complex media may also include some components and protein that are synthesized by bacteria. We think that after the production of LALF, the protein can pass to biofilm with the help of signal peptides we added. As long as LALF remains in the biofilm, the surface that is covered with that biofilm material will not be infected by gram negatives.

Mustafa--lalf.png (610×496)Gjhjgöhkçj..png (592×956)

The LPS coat of gram negative bacteria is an important reason of endotoxin and septic shock. LALF binds to that LPS coat and inhibits the growth of bacteria. This ability is very crucial and may be very useful considering the diseases and pandemics that are caused by gram negatives. Our project suggests a possible prevention for such circumstances.
Also, by killing spores of B.subtilis on the biofilm surface with aqueous dissolved oxygen, ascorbic acid, and copper ions, we will try to perform a sterilized coating material which will possess a protective feature against infectious gram negative bacteria.

REFERENCES

  1. Alpert G, Baldwin G, Thompson C, Wainwright N, Novitsky T J, Gillis , Parsonnet J, Fleisher G R, Siber G R. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J Infect Dis. 1992;165:494–500. [PubMed]
  2. Bannerman D D, Goldblum S E. Endotoxin induces endothelial barrier dysfunction through protein tyrosine phosphorylation. Am J Physiol. 1997;273:L217–L226. [PubMed]
  3. Battafaraono R J, Dahlberg P S, Ratz C A, Johnston J W, Gray B H, Haseman J R, Mayo K H, Dunn D L. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery. 1995;118:318–324. [PubMed]
  4. Cooperstock M S. Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother. 1974;6:422–425. [PMC free article] [PubMed]
  5. Evans T J, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram negative sepsis. J Infect Dis. 1995;171:153–160. [PubMed]
  6. Fletcher M A, Mckena T M, Quance J L, Wainwright N R, Williams T J. Lipopolysaccharide detoxification by endotoxin neutralizing protein. J Surg Res. 1993;55:147–154. [PubMed]
  7. Frey E A, Miller D S, Jahr T G, Sundan A, Bazil V, Espevik T, Finlay B B, Wright S D. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665–1671. [PMC free article] [PubMed]
  8. Goldblum S E, Brann T W, Ding X, Pugin J, Tobias P S. Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. J Clin Invest. 1994;93:692–702. [PMC free article] [PubMed]
  9. Goldblum S E, Ding X, Brann T W, Campbell-Washington J. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: concurrent F-actin depolymerization and new actin synthesis. J Cell Physiol. 1993;157:13–23. [PubMed]
  10. Hirata M, Zhong J, Wright S C, Larrick J W. Structure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res. 1995;392:317–326. [PubMed]
  11. Hoess A, Watson S, Siber G R, Liddington R. Crystal structure of endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution. EMBO J. 1993;12:3351–3356. [PMC free article] [PubMed]
  12. Levine D M, Parker T S, Donelly T M, Walsh A, Rubin A L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA. 1993;90:12040–12044. [PMC free article] [PubMed]
  13. Morita T, Ohtsubo S, Nakamura T, Tanaka S, Iwanaga S, Ohashi K, Niwa M. Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS) J Biochem (Tokyo) 1985;97:1611–1620. [PubMed]
  14. Morrison D C, Jacobs D M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976;13:813–818. [PubMed]
  15. Muta T, Miyata T, Tokunaga F, Nakamura T, Iwanaga S. Primary structure of anti-lipopolysaccharide factor from American horseshoe crab, Limulus polyphemus. J Biochem (Tokyo) 1987;101:1321–1330. [PubMed]
  16. Netea M G, Demacker P N M, Kullberg B J, Boerman O C, Verschueren I, Stalenhoef A F H, van der Meer J W M. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest. 1996;97:1366–1372. [PMC free article] [PubMed]
  17. Ulevitch R J, Tobias P S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol. 1994;6:125–130. [PubMed]
  18. Wainwright N R, Miller R J, Paus E, Novitsky T J, Fletcher M A, McKenna T M, Williams T. Endotoxin binding and neutralizing activity by a protein from Limulus polyphemus. In: Levin J, Alving C R, Munford R S, Stutz P L, editors. Cellular and molecular aspects of endotoxin reactions. New York, N.Y: Elsevier Science Publishers; 1990. pp. 315–325.
  19. Warren H S, Novitsky T J, Bucklin A, Kania S A, Siber G R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria. Infect Immun. 1987;55:1668–1673. [PMC free article] [PubMed]
  20. Weinstein S L, June C H, DeFranco A L. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. J Immunol. 1993;151:3829–3838. [PubMed]
  21. A. Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.
  22. Lihua Wu, Chao-Ming Tsai and Carl E. Frasch.A method purification of bacterial R-type LPS.
  23. Kloczewiak, M., Black, K. M., Loiselle, P., Cavaillon, J. M., Wainwright, N., and Warren, H. S. (1994) J. Infect. Dis. 170, 1490–1497
  24. http://www.horseshoecrab.org
2011 © Fatih Medical School

Retrieved from "http://2011.igem.org/Team:Fatih_Turkey/LALF"